

Original Research Article

In vitro Anti-Leishmania Activity and Safety of Newly Synthesized Thiazolo Pyrimidine Derivatives Augmented with Interleukine-12 (IL-12) in BALB/c Mice Experimentally-Infected with Cutaneous Leishmaniasis

Saleh A Bahashwan^{1*}, Mohamed A Ramadan², Moutasem S Aboonq³ and Ahmed A Fayed⁴

¹Pharmacology and Toxicology Department, College of Pharmacy, ²Microbiology/Immunology Department, ³Physiology Department, College of Medicine, ⁴Respiratory Therapy Department, College of Medical Rehabilitation Sciences, Taibah University, Medina Munawarah, Saudi Arabia

*For correspondence: **Email:** bhswan@yahoo.com; **Tel:** +966-590045053

Received: 9 May 2015

Revised accepted: 7 October 2015

Abstract

Purpose: To synthesize a series of novel thiazolo pyrimidine derivatives and evaluate them *in vitro* and *in vivo* for their safety and anti-leishmanial activity using BALB/c mice.

Methods: Substituted pyrazolopyrimidine and pyrazolopyrazole were synthesized by reacting amino group of 2-amino-4-cyano-pyrazol[naphthalino[1,2-d]thiazole with a variety of formamide or hydrazine hydrate. The synthesized compounds were characterized by nuclear magnetic resonance spectroscopy (¹H-NMR) and mass spectroscopy (MS). The purity of the compounds was determined by elemental analysis. Safety and anti-leishmanial activity of the compounds were determined *in vitro* by i) viability assessment of leishmania-infected macrophages, relative abundance of IL-12p40 mRNA gene expression and levels of IL10/IL-12 determination in supernatants of cultured macrophages treated with 2.5 and 10 μM of the compounds, using microscope cell counting, reverse transcriptase polymerase chain reaction (RT-PCR) and enzyme linked immunosorbent assay (ELISA), respectively. ii) cytotoxicity of the compounds evaluated by determination the safety index as IC₅₀ of the compound in macrophages/IC₅₀ of the compound in amastigotes. iii) bioassay at 16 weeks post-infection of mice treated with the reference drug, the tested compound alone and both the compound with IL-12. Disease progression and footpad thickness were evaluated regularly during treatment.

Results: Compound 4 emerged as the most active anti-protozoal compound of the series against *Leishmania* viability (activity 60 %) compared with the reference drug (activity 65 %). When it was combined with IL-12, the activity reached 90 %.

Conclusion: Compound 4 can serve as a lead molecule for further development to a clinically useful novel class of agents.

Keywords: Thiazolopyrimidine, Synthesis, Leishmaniasis, Mice, Immunotherapy

Tropical Journal of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals (DOAJ), African Journal Online, Bioline International, Open-J-Gate and Pharmacy Abstracts

INTRODUCTION

Leishmaniasis, caused by the protozoan parasite of the genus *Leishmania*, affects over 12 million

individuals worldwide, 1.5 – 2 million of whom develop symptomatic disease every year [1]. The parasite is spread by the sand fly vector and causes a spectrum of diseases depending on the

parasite species and the host immune status. Clinical manifestations of the disease range from self-limiting cutaneous Leishmaniasis, disfiguring muco-cutaneous Leishmaniasis, to fatal visceral leishmaniasis. Current treatment use toxic antimonial compounds. These treatments are laborious and expensive, cause severe side effects and emerging drug resistance has been reported [2]. Therefore, an alternative effective treatment regime would be desirable.


Immunity against *L. major* infection is well characterized in the mouse model and depends mainly on T-helper1 (Th1) immune responses mediated by CD4⁺ T cells induced by the essential cytokine IL-12 [3]. As *Leishmania* reside within macrophages, they deviously manipulate the host innate and acquired immune mechanisms. This ensures their survival within the hostile environment of macrophages and hinges on their capacity to modulate macrophage effect or functions including production of reactive nitrogen intermediates, RNI [4]. Macrophages can induce host cells to produce cytokines that promote disease progression via regulation of Th1 and Th2 cells. The Th1 cells by secreting IFN- γ enhance macrophage microbial activity, thus protecting the host from intracellular *Leishmania* pathogens [5]. Conversely, the parasite for survival cleverly augments Th2 response, leading to an increased secretion of IL-4 and IL-10, resulting in attenuation of the host mechanisms and *Leishmania* infection ensues [6].

Newly synthesized pyrimidine and pyrazolo derivatives are well documented [7,8]. Heterocyclic compounds exhibit anthelmintic, anti HIV activity and hypoglycemic activity [9], anti-microbial, analgesic [10,11], against herpes simplex virus type-1 (HSV-1) and hepatitis-A virus (HAV), serotonin 5-HT₆ receptor antagonist [12], antitumor activity and anticancer activity [13]. Thiazolopyrimidines have hypoglycemic, hypolipidemic, anti-diabetic, [14] and antimalarial [15,16]. As an extension of our ongoing studies, the objective of the present work is to synthesize new compounds and evaluates them both *in vitro* and *in vivo* for their anti-protozoal activities against experimental cutaneous Leishmaniasis in mice.


EXPERIMENTAL

In a previous work, we have reported the synthesis of substituted pyrazolopyrimidine **3** and pyrazolopyrazole **4** by using 1-(naphtho[1,2-d]thiazol-2-yl)hydrazine **1** as starting material. The starting material **1** was synthesized according to the previous procedure [17] (Scheme 1).

The reaction of compound **1** with ethoxymethylene malomonitrile afforded the corresponding 3-amino-4-cyanopyrazolo derivatives **2**, which was treated with formamide or hydrazine hydrate to produce the corresponding 3-aminopyrazolopyrimidine **3** and aminopyrazolopyrazole derivative **4**, respectively [18] (Scheme 2).



Scheme 1: Synthetic route of 1-(naphtho[1,2-d]thiazol-2-yl)hydrazine **1**



Scheme 2: Synthetic route of compounds 2-4

Synthesis of 2-[3-amino-4-cyano-pyrazol-2-yl]naphthalino [1,2-d]thiazole (2)

A mixture of compound **1** (0.01 mol) and ethoxymethylene malononitrile (0.01 mol) in absolute ethanol (30 mL) was refluxed for 2h. The solvent was evaporated under reduced pressure; the residual solid was crystallized from ethanol to give the title product **2** as yellow powder. Yield 87 %; m.p. 256-258 °C; IR (KBr, cm^{-1}): 3345-3315 (NH_2) and 2215 (CN) cm^{-1} ; $^1\text{H-NMR}$ (DMSO- d_6): δ = 6.78-7.61 (m, 7H, 6Ar-H and 1H_{Pyrazolo}) and 10.43 (b, 2H, NH_2 exchangeable with D_2O) ppm; MS m/z (%) = 291 (M^+ , 23) corresponding to the molecular formula $\text{C}_{15}\text{H}_9\text{N}_5\text{S}$ and at 184 (100, base peak).

Synthesis of 2-[6-aminopyrimidino[4,5-c]pyrazol-2-yl]naphthalino[1,2-d]thiazole (3)

A solution of compound **2** (0.01 mol) in formamide (20 ml) was refluxed for 2h. After cooling, the solid product was collected by filtration, dried and crystallized from methanol to give the title product **3** as reddish brown powder. Yield 66 %; m.p. 290-292 °C; IR (KBr, cm^{-1}): 3325 (NH_2) cm^{-1} ; $^1\text{H-NMR}$ (DMSO- d_6): δ = 6.64-7.52 (m, 8H, 6Ar-H, 1H_{Pyrazolo} and 1H_{Pyrimidino}) and 11.12 (b, 2H, NH_2 exchangeable with D_2O) ppm; MS m/z (%) = 318 (M^+ , 19) corresponding to the molecular formula $\text{C}_{16}\text{H}_{10}\text{N}_6\text{S}$ and at 120 (100, base peak).

Synthesis of 2-[5-amino-3H-pyrazolo[3,4-c]pyrazol-2-yl]naphthalino[1,2-d]thiazole (4)

A mixture of compound **2** (0.01 mol), and hydrazine hydrate (0.01 mol) in acetic acid (30

mL) was refluxed for 3 h. The reaction mixture was poured onto ice cold water. The solid was filtered off, dried and crystallized from ethanol to give title product **4** as green powder. Yield 69 %; mp > 300 °C; IR (KBr, cm^{-1}): 3372-3323 (NH , NH_2) cm^{-1} ; $^1\text{H-NMR}$ (DMSO- d_6): δ = 6.15 (s, 1H, NH exchangeable with D_2O), 7.21-7.58 (m, 7H, 6Ar-H and 1H_{Pyrazolo}) and 11.42 (b, 2H, NH_2 exchangeable with D_2O) ppm; MS m/z (%) = 306 (M^+ , 31) corresponding to the molecular formula $\text{C}_{15}\text{H}_{10}\text{N}_6\text{S}$ and at 184 (100, base peak).

Animals

Five to 6- week- old BALB/c mice of either sex, 16-18 g each were purchased from Theodor Bilharz Research Institute TBRI, Egypt. Approval of the institutional Animal Ethical Committee for the animal studies was obtained from the Office of Environmental Health and Radiation Safety (ACUC protocol # 1096-5). The animals were maintained according to accepted standards of human care [19]

Parasite culture

Promastigotes from Indian *Leishmania donovani* isolate (NS2) were routinely passaged in mice and after transformation, cultured at 24 °C in medium 199 supplemented with 10 % heat inactivated fetal calf serum (HIFCS), Penicillin G (50 IU/mL) and Streptomycin (50 $\mu\text{g}/\text{mL}$). For infection of macrophages, 24 h prior to the experiment, stationary phase promastigotes were centrifuged and the pellet re-suspended in Schneider's insect medium supplemented with 20 % HIFCS, pH 5.5, as described by [20]

In vitro anti-amastigote activity in macrophages

Peritoneal macrophages lavaged from BALB/c mice were seeded in 16 chamber slides (1.5 x 10⁵/200 µl/well of complete RPMI-1640 medium) and after a 2 - 4 h incubation at 37 °C, 5 % CO₂, the supernatants (containing lymphocytes) were gently removed and kept aside at 37 °C, 5 % CO₂. Adherent macrophages were then infected with stationary phase *L. donovani* promastigotes (preconditioned at 25 °C for 24 h in Schneider's insect medium pH 5.5 at a macrophage: parasite ratio of 1: 10 and incubated for 5 h at 37 °C, 5 % CO₂. After removal of non-internalized parasite, macrophages were then co-cultured with the above mentioned supernatants in the presence or absence of compound 3 and compound 4 separately at a dose of (0 - 25 µM) for 72 h, after which cells were fixed., Giemsa-stained (diluted 1:7 in deionized water, pH 6.8) and examined microscopically for intracellular amastigotes. At least 100 macrophages/well were counted to calculate the percentage of infected macrophages. The infection rate of treated macrophages was normalized to 100 % for further analysis.

Safety index of the synthetic compounds

To investigate the cytotoxicity of the compounds, murine macrophages (1.5 x 10⁵/200 µl/well) were incubated with the compounds (0 - 100 µM) at 37 °C, 5 % CO₂ for 48, 72 and 96 h and cell viability enumerated as described by [21]. The safety index was calculated as the IC₅₀ of the compound in macrophages/ IC₅₀ of compound in amastigotes.

Reverse transcriptase polymerase Chain reaction (RT-PCR)

Total RNA was isolated using the RNAqueous Kit from normal and *Leishmania*-infected macrophages (obtained from BALB/c mice) after being treated the tested compound (2.5 and 10 µM) for 18 h. Subsequently, RT-PCR was carried out with the one-step RT-PCR kit using (200 ng/reaction) that was reverse-transcribed into cDNA and amplified, using gene-specific primers as described previously [22].

IL-10 and IL-12 measurement using sandwich ELISA

Levels of mouse IL-10 and IL-12p40 present in the supernatants of uninfected and *L. donovani* infected macrophages that had been treated with the compounds for 24 h were measured using an ELISA kit as per the manufacturer's instruction. A

standard curve with a cytokine-positive control was run in each assay, the lower limit of detection being 31.24 pg/mL for IL-10 and 15.0 pg/mL for IL-12p40.

Parasite Infection and tissue studies

Mice were inoculated in one hind footpad with metacyclic promastigotes. A total of 1-2 x 10⁵ highly infective stage metacyclic promastigotes was isolated from stationary culture (5-7 d old) by negative selection using peanut agglutinin (Vector laboratories, Burlingame, CA) and injected subcutaneously in the left footpad. The infected footpad was kept under observation 16 weeks after infection for redness, swelling, ulceration, crust formation or gangrenous changes. The evolution of the lesion was monitored weekly by measuring footpad thickness using metric caliper (Mitutoyo Measuring Instruments, Aurora, IL). The degree of infection in parasitized footpad lesions was determined by limiting dilution analysis of homogenized tissue. To determine parasite concentrations, footpads were weighed and homogenized. Two-fold serial dilutions of the homogenized tissue suspensions were then plated in 96-well plates and incubated at 26 °C for 7-10 days. Wells were examined for viable and motile promastigotes, and the highest dilution that was positive for parasites was considered to be the parasite concentration per milligram of tissue. The total parasite burden was calculated using the weight of the footpad, as previously described [23].

Animal's treatment regime

Sodium stibogluconate (Pentostam, Burroughs Welcome, London, United Kingdom) containing 100 mg of pentavalent antimony per ml) was a gift of Max Grog, Walter Reed Army Institute of Research, Washington, D.C. Mouse recombinant IL-12, kindly provided by Giorgio Trinchieri (Wistar Institute, Philadelphia, PA). Animals were divided into experimental groups (GPs), 45 mice each, GP1: untreated infected control, received intradermal injection of 2 x 10⁷ viable promastigotes in the right footpad; GP2: Infected and treated with the reference drug (Sodium stibogluconate), each mice received a total of 10 daily intramuscular injections with 250 mg of drug per kg of body weight during weeks 3 and 4 of infection; GP3: infected and treated with compound 4, each mice received a total of 10 daily intramuscular injections with 25 mg of the compound per kg of body weight during weeks 3 and 4 of infection; GP4: infected and treated with compound 4 as mentioned before + IL-12 (0.1 mL containing 0.1 µg of IL-12) intraperitoneally

on day 15 of infection with an additional dose on day 22 of infection. One group was used as normal non-infected control, injected with 0.1 mL sterile saline in the right hind footpad.

Statistical analysis

The results are expressed as mean \pm SD/SEM as indicated. Statistical analysis was based on one-way ANOVA followed by Turkey's Multiple Comparison Test using Graph Pad Prism software, version 4. $P < 0.05$ was considered as statistically significant.

RESULTS

Anti-leishmanial activity of the synthesized compounds

The anti-leishmanial activity of the synthetic compounds (0 - 25 μ M) was evaluated in terms of the intracellular parasite load, wherein the infection rate of *Leishmania* infected macrophages was normalized to 100 %; with the addition of the tested compound, a dose dependent reduction in parasitic load was evident, the IC_{50} being 2.5 μ M (Fig. 1). In macrophages, 92 % were parasitized and the average number of amastigotes/macrophage was 11.3. After treatment with the tested compound (72 h), the percentage of infected macrophages decreased in a dose-dependent manner. With 10 μ M of the compound, only 59 % of macrophages were infected, the number of amastigotes/macrophage being 1.7.




Figure 1: Anti-amastigote activity and safety index of the tested compound. Each point corresponds to the mean \pm SD of at least three experiments in duplicate

The synthetic compounds enhanced mRNA expression of IL-12p40

In uninfected macrophages, the tested compound (2.5 and 10 μ M) induced an increase

in mRNA expression of IL-12p40. Following infection with *Leishmania* parasites (as confirmed by Giemsa staining), a down regulation in mRNA expression of IL-12p40 was observed, which was reversed by the tested compound (Fig. 2).




Figure 2: Effect of the tested compound on mRNA gene expression of IL-12p40 in macrophages

This genetic up-regulation of IL-12p40 by the tested compound was correlated by quantifying levels in culture supernatants by ELISA. In uninfected macrophages, the mean \pm SEM was 495.00 ± 26.53 pg/mL, which with the tested compound (2.5 and 10 μ M) significantly increased by 1.85 and 1.9 fold ($p < 0.001$) respectively. Following successful intracellular *Leishmania* infection, levels of IL-12 reduced significantly by 1.7 fold, ($p < 0.001$), importantly, treatment with the synthetic compound (2.5 and 10 μ M) significantly increased production of IL-12p40 to 550.8 ± 60.5 ($p < 0.05$) and 595.1 ± 32.98 pg/mL ($p < 0.01$) respectively compared with infected macrophages (Fig. 3). The tested compound (2.5 and 10 μ M), significantly decreased the secretion of IL-10 as compared with the infected macrophages (data not shown).




Figure 3: Effect of the tested compound on IL-12p40 level in macrophages culture supernatants Each point represents the mean \pm SEM of IL-12p40 (pg/mL) of at least 3 experiments in duplicate

Cutaneous lesion and the parasitological footpad tissue studies

Early onset was observed in the infected control group (GP1), where swelling, ulceration and gangrene formation were observed in the majority of mice and the lesion developed up to total gangrene and auto-amputation. Later onset was observed in the reference drug treated group (GP2), up to ulceration with minority of mice developed gangrene and only 2 mice developed auto-amputation. Also, the latest onset was observed in the compound 4 treated group (GP3) and the combination treated group (GP4) up to ulceration with no gangrene or amputation, where the ulcers were slow developing, healing and only observed in the minority of mice as shown in (Table 1). There was a dramatic lessening of disease progression, as seen by reduction of footpad swelling in mice treated with the compound 4 combined with IL-12 compared with the infected control group, (data not shown).

DISCUSSION

In a previous work, we have reported the synthesis of pyrazolopyrimidine and pyrazolopyrazole derivatives using hydrazinothiazole **1** as starting material. The reaction of α -amino naphthol with KSCN produced 2 amino thiazolo derivatives. The reaction of 2-amino thiazolo derivatives with sodium nitrite and hydrochloric acid produced the corresponding diazotium salt, which converted to 2- hydrazine thiazolo derivatives **1** (Scheme 1). Reaction of hydrazinothiazolo derivatives **1** with ethoxymethylene afforded compound **2**, which reacted to formamide and hydrazine hydrate respectively to produce pyrazolopyrimidine **3** and pyrazolopyrazole **4** respectively (Scheme 2). All the synthesized compounds were confirmed by spectral data (IR, ¹H-NMR and mass spectra). Structure-activity relationships based on the

obtained results indicated that substitution of 2-[6-aminopyrimidino[4,5-c]pyrazol-2-yl]naphthalino [1,2-d]thiazole **3** derivatives had anti-leishmanial activity and safety effect.

We initially investigated whether the new synthetic compounds **3** and **4** affect the amastigote activity inside *Leishmania* infected macrophages and affect the IL-12 mRNA gene expression with IL-10, IL-12 cytokines secretion levels. In uninfected macrophages, the tested compounds (2.5 and 10 μ M) induced an increase of IL-12p40 mRNA gene expression. Following infection with *Leishmania* parasite a down-regulation of this protein was observed, which was reversed by our new synthetic compounds. This genetic up-regulation was correlated with the increased levels of IL-12 after treatment of infected macrophages with the compounds.

Animal studies showed that compound **4** treated group (GP3) achieved a maximum delayed onset of cutaneous Leishmaniasis disease progression with a decrease of footpad thickness and parasite density in the infected footpad compared with the infected control group (GP1), specifically when combined with the immunotherapeutic agent IL-12 (GP4). Our results showed the anti-leishmanial activity of the synthetic compounds were in consistence with previous results showed that hetero-cyclic compounds were potent anthelmintic, anti-fungal and anti-malarial agents [10-16]

CONCLUSION

The results indicate that the synthesized heterocyclic organic compounds, a new series of substituted pyrazolopyrimidine **3** and pyrazolopyrazole **4**, are promising agents for the development of new antiprotozoal candidates for enhanced safety and pharmacological efficacy when augmented with immunotherapy IL-12 for the treatment of cutaneous leishmaniasis.

Table 1: Onset of cutaneous lesion development in different studied groups (**Note:** number of mice in parenthesis)

Animal group	Redness	Swelling	Ulceration	Partial gangrene (No. of mice)	Total gangrene (No. of mice)	Auto-amputation
GP1	7 th day	10 th day	5 wks (45)	10 wks (35)	12 wks (42)	14 wks (40)
GP2	10 th day	14 th day	6 wks (25)	12 wks (15)	14 wks (10)	16 wks (2)
GP3	17 th day	24 th day	8 wks (10)	None	None	None
GP4	20 th day	28 th day	9 wks (5)	None	None	None

GP1= infected control; GP2= Infected and treated with the reference drug; GP3= Infected and treated with compound 4; GP4= Infected and treated with both compound 4 and IL-12

ACKNOWLEDGEMENT

This work was fully supported by the Scientific Research Deanship, Taibah University, Ministry of Higher Education, Saudi Arabia (Grant # 3084/434). The authors are grateful to Taibah University President and the Dean of Scientific Research for their support.

REFERENCES

1. Ameen M. Cutaneous leishmaniasis, advances in disease pathogenesis, diagnosis and therapeutics. *Clin Exp Dermatol* 2010; 35: 699–705.
2. Ait-Oudhia K, Gazanion E, Vergnes B, Oury B, Sereno D. *Leishmania antimony resistance: what we know what we can learn from the field. Parasitol Res* 2011; 109(5): 1225-1232.
3. Mougneau E, Bihl F, Glaichenhaus N. *Cell biology and immunology of Leishmania. Immunol Rev* 2011; 240: 286–296.
4. Nadeer T, McConville MJ. *The Leishmania-macrophage interaction: a metabolic perspective. Cell Microbiol* 2008; 10: 301-308.
5. Roberts MT. *Current understanding on the immunology of Leishmaniasis and recent developments in prevention and treatment. Br Med Bull* 2006; 75-76: 115-130.
6. Kane MM, Moser DM. *The role of IL-10 in promoting disease progression in Leishmaniasis. J Immunol* 2001; 166: 1141-1147.
7. Namazi H, Mirzaei YR, Azamat H. *Investigation the Chemical Reactivity of Positions N-3, C-5 and C-6-Methyl Group in Biginelli type Compounds and Synthesis of New Dihydropyrimidine Derivatives. J Hetero Chem* 2001; 38(5): 1051-1054.
8. Kheder NA, Mabkhot YN, Farag AM. *A convenient access to new pyrido[4,3-d]pyrimidine, thiazolo[3,4-c]pyrimidine and pyrimido[4,5-d]pyridazine derivatives. Arkivoc* 2008; 17: 107-116.
9. Rao A, Balzarini J, Cafbone A, Chimirri A. *2-(2,6-Dihalophenyl)-3-(pyrimidin-2-yl)-1,3-thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors. Antiviral Res* 2004; 63(2): 79-84.
10. Fayed AA, Hosni HM, Flefel EM, Amr AE. *Synthesis and Pharmacological Activity of Some New Thino Pyrimidine and Pyrimido pyrazolo thino pyrimidine Derivatives. W J Chem* 2009; 4(1): 58-65.
11. Bahashwan SA. *Pharmacological studies of some pyrimidino derivatives. Afri J Pharm and Pharmacol* 2011; 5(4): 527-531.
12. Ramakrishna VS, Kambhampati RS, Kothmirkar P, Arepalli S, Reddy GN. *Convenient and Efficient Synthesis of Some Novel Fused Thieno Pyrimidines Using Gewald's Reaction. Synth Comm* 2011; 41(19): 2835-2851.
13. Abdel-hafez NA, Mohamed AM, Amr AE, Abdalla MM. *Antiarrhythmic Activities of Some Newly Synthesized Tricyclic and Tetracyclic Thienopyridine Derivatives. Sci Pharm* 2009; 77: 539-553.
14. Lee HW, Kim BY, Ahn JB, Kang SK, Lee JH, Shin JS, Ahn SK, Lee SJ, Yoon SS. *Molecular design, synthesis, and hypoglycemic and hypolipidemic activities of novel pyrimidine derivatives having thiazolidinedione. Eur J Med Chem* 2005; 40(9): 862-874.
15. Sunny MS, Chinna Rajesh UC, Khan SI, Tekwani BL, Rawat DS. *Novel 4-Aminoquinoline-Pyrimidine Based Hybrids with Improved in Vitro and in Vivo Antimalarial Activity. ACS Med Chem Lett* 2012; 3(7): 555–559.
16. Christian DJ, Bhoi MN, Mayuri A, Borad MA, Rajani DP, Rajani SD, Patel HD. *Microwave Assisted Synthesis and in Vitro Anti-malarial Screening of Novel Pyrimidine Derivatives. W J Pharm Pharmaceut Sci* 2014; 3(8): 1955-1971.
17. Fayed AA and Ghanem S. *Anti-microbial evaluation of new thiazolo pyrimidine derivatives. Eur Sci J* 2013; 9 (33): 1857-7881.
18. Bahashwan SA, Fayed AA, Ramadan MA, Amr AE, Al-Harbi NO. *Androgen Receptor Antagonists and Anti-Prostate Cancer Activities of Some Newly Synthesized Substituted Fused Pyrazolo-, Triazolo- and Thiazolopyrimidine Derivatives. Int J Mol Sci* 2014; 15(11): 21587–21602.
19. Mahmoud AAF. *In: Tropical and Geographical Medicine, McGraw-Hill, New York, 1984; p 443.*
20. Da Luz RI, Vermeersch M, Dujardin JC, Cos P, Maes L. *In vitro sensitivity testing of Leishmania clinical field isolates: preconditioning of promastigotes enhances infectivity for macrophages host cells. Antimicrob Agents Chemother* 2009; 53: 5197-5203.
21. Ganguly S, Bandyopadhyay S, Sakar A. *Development of a semi-automated colorimetric assay for screening anti-leishmanial agents. J Microbiol Methods* 2006; 66: 79-86.
22. Ganguly S, Mula S, Chattopadhyay S, Chatterjee M. *An ethanol extract of piper betle Linn. Mediates its anti-inflammatory activity via down-regulation of nitric oxide. J Pharm Pharmacol* 2007; 59: 711-718.
23. Raman VS, Bhatia A, Picon A, Whittle J, Bailor HR, O'Donnell J, Pattabhi S, Guderian JA, Mohamath R, Duthie MS, Reed SG. *Applying TLR Synergy in Immunotherapy: Implications in Cutaneous Leishmaniasis J Immunol* 2010; 185: 1701-1710.